Zapping remaining tumors could extend life for lung cancer patients
NCT ID NCT07379476
Summary
This trial is for people with a specific type of advanced lung cancer (EGFR-mutated NSCLC) who have responded well to their first-line pill, osimertinib, but still have a few small, leftover cancer spots. It tests whether adding a targeted, high-dose radiation treatment (called local ablative therapy) to those leftover spots, while continuing the pill, helps control the cancer longer than just taking the pill alone. The main goal is to see if this combined approach increases the time patients live without their cancer getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Clinical Oncology, Prince of Wales Hospital
RECRUITINGHong Kong, Hong Kong
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.